ANGO · Angiodynamics Inc
Market Cap
$619.99M
Shares
41.33M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$320.17M
+9.5%
FY2026
Net Income
-$36.74M
-8.1%
FY2026
Gross Margin
54.62%
+0.7pp
FY2026
Operating Margin
-12.47%
+1.2pp
FY2026
Diluted EPS
-$0.88
-6%
FY2026
Operating Cash Flow
$3.09M
+130.5%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $320.17M | $292.5M | $303.91M | $338.75M | $316.22MG | $291.01M | $264.16M | $270.63M | $261.66M | $269.79M | $353.89M | $356.53M | $354.43M | $341.92M | $221.92M | $215.62M | $216.04M | |
| — | $145.28M | $134.79M | $149.22M | $164.51M | $150.49M | $134.22M | $113.89M | $114.63M | $117.8M | $125.84M | $179.57M | $180.74M | $174.25M | $173.4M | $96.61M | $90.05M | $89.07M | |
| — | $174.89M | $157.71M | $154.7M | $174.25M | $165.73M | $156.79M | $150.27M | $156M | $143.86M | $143.95M | $174.32M | $175.8M | $180.17M | $168.51M | $125.31M | $125.57M | $126.97M | |
| — | 54.62% | 53.92% | 50.9% | 51.44% | 52.41% | 53.88% | 56.89% | 57.64% | 54.98% | 53.36% | 49.26% | 49.31% | 50.84% | 49.29% | 56.47% | 58.24% | 58.77% | |
| — | $29.45M | $26.22M | $31.51M | $29.88M | $30.74M | $36.39M | $29.68M | $28.26M | $24.34M | $24.15M | $25.05M | $26.59M | $28.12M | $26.09M | $20.51M | $21.37M | $19.28M | |
| — | $113.4M | $103.14M | $102.82M | $104.25M | $95.3M | $81.31M | $78.63M | $76.83M | $73.11M | $74.87M | $83.74M | $82.35M | $85.31M | $77.56M | $65.76M | $58.12M | $60.92M | |
| — | $43.69M | $42.09M | $41.16M | $40M | $38.45M | $35.92M | $37.87M | $34.9M | $30.99M | $31.13M | $30.58M | $30.03M | $26.9M | $26.04M | $19.03M | $17.83M | $16.44M | |
| — | $10.68M | $10.32M | $13.05M | $18.79M | $19.46M | $18.14M | $18.12M | $17.06M | $13.91M | $14.57M | $17.96M | $17.97M | $16.56M | $16.6M | $9.39M | $9.23M | $9.46M | |
| — | $22.96M | $25.8M | $27.71M | $30.87M | $29.35M | $25.92M | $23.81M | $25.88M | $23.16M | $24.81M | $28.12M | $29.86M | $28.33M | $27.23M | $14.68M | $12.58M | $12.46M | |
| — | $13.12M | $13.76M | — | — | — | — | $26K | $288K | $4.67M | $1.35M | $0 | — | — | — | — | — | — | |
| — | $214.82M | $197.66M | $401.63M | $225.43M | $194.2M | $192.07M | $317.37M | $165.4M | $158.03M | $155.13M | $173.3M | $179.25M | $169.69M | $163.27M | $130.55M | $113.67M | $106.1M | |
| — | -$39.93M | -$39.95M | -$192.44M | -$51.18M | -$28.47M | -$35.28M | -$167.1M | -$9.4M | -$14.17M | -$11.18M | $1.02M | -$3.45M | $10.49M | $5.24M | -$5.24M | $11.9M | $20.87M | |
| — | -12.47% | -13.66% | -63.32% | -15.11% | -9% | -12.12% | -63.26% | -3.47% | -5.42% | -4.14% | 0.29% | -0.97% | 2.96% | 1.53% | -2.36% | 5.52% | 9.66% | |
| — | -$16.97M | -$14.15M | -$164.72M | -$20.31M | $878K | -$9.37M | -$143.29M | $16.48M | $8.99M | $13.64M | $29.13M | $26.41M | $38.82M | $32.47M | $9.43M | $24.48M | $33.33M | |
| — | — | — | -$1.61M | $2.7M | $688K | $861K | $907K | $5.1M | $3.06M | $2.84M | $3.39M | $3.19M | $3.66M | $5.27M | $508K | $499K | $672K | |
| $22K | — | — | — | — | — | — | — | — | — | — | $11K | $4000 | $0 | $103K | $1.09M | $737K | $713K | |
| — | $3.93M | $4.94M | -$817K | -$554K | -$790K | $92K | -$130K | -$207K | -$3.09M | -$3.12M | -$4.27M | -$4.68M | -$5.3M | -$6.58M | -$409K | -$1.27M | -$1.25M | |
| — | -$36.3M | -$34.03M | -$191.64M | -$54.44M | -$29.95M | -$36.05M | -$168.14M | -$14.7M | -$17.26M | -$14.3M | -$3.25M | -$8.13M | $5.19M | -$1.34M | -$5.65M | $10.64M | $19.62M | |
| — | $442K | -$39K | -$7.29M | -$2M | -$3.4M | -$4.5M | -$1.35M | -$3.56M | -$11.04M | -$7.24M | $40.34M | -$4.74M | -$9.2M | -$286K | -$322K | $2.56M | $7.31M | |
| — | -$36.74M | -$33.99M | -$184.35M | -$52.44M | -$26.55M | -$31.55M | -$166.79M | $61.34M | $16.34M | $5.01M | -$43.59M | -$3.39M | $2.35M | -$1.05M | -$5.33M | $8.08M | $12.31M | |
| — | -11.48% | -11.62% | -60.66% | -15.48% | -8.4% | -10.84% | -63.14% | 22.67% | 6.24% | 1.86% | -12.32% | -0.95% | 0.66% | -0.31% | -2.4% | 3.75% | 5.7% | |
| — | -$27.04M | -$31.65M | -$183.99M | -$58.52M | -$28.34M | -$27.05M | -$166.78M | $60.94M | $16.71M | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$0.88 | -$0.83 | -$4.59 | -$1.33 | -$0.68 | -$0.82 | -$4.39 | $1.64 | $0.44 | $0.14 | -$1.21 | -$0.09 | $0.07 | -$0.03 | -$0.20 | $0.33 | $0.50 |
| USD/shares | — | -$0.88 | -$0.83 | -$4.59 | -$1.33 | -$0.68 | -$0.82 | -$4.39 | $1.64 | $0.44 | $0.14 | -$1.21 | -$0.09 | $0.07 | -$0.03 | -$0.20 | $0.32 | $0.50 |
| shares | — | 41.53M | 40.85M | 40.18M | 39.48M | 39.01M | 38.34M | 37.96M | 37.48M | 37.07M | 36.62M | 36.16M | 35.68M | 35.14M | 34.82M | 25.38M | 24.87M | 24.58M |
| shares | — | 41.53M | 40.85M | 40.18M | 39.48M | 39.01M | 38.34M | 37.96M | 37.48M | 37.07M | 36.62M | 36.16M | 35.68M | 35.44M | 34.82M | 25.38M | 25.13M | 24.79M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2026: $17.33M in buybacks, $0 in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 38 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.36×
EV/EBIT
—
Peer median 27.69×
P/E (TTM)
—
Peer median 33.42×
Peer medians compare against the 20 similar-size Medical Instruments & Supplies companies (of 44 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Med Device Segment | $170,220,000 | $165,845,000 | $197,511,000 | $242,065,000 |
| Med Tech Segment | $149,954,000 | $126,653,000 | $106,403,000 | $96,687,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $274,923,000 | $250,983,000 | $251,486,000 | $282,713,000 | $265,963,000 | $237,043,000 | $207,980,000 | $216,957,000 |
| Non Us | $45,251,000 | $41,515,000 | $52,428,000 | $56,039,000 | $50,256,000 | $53,967,000 | $56,177,000 | $53,677,000 |
| International | — | — | — | $56,039,000 | $50,256,000 | $53,967,000 | $56,177,000 | $53,677,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Med Device Segment | $170,220,000 | $165,845,000 | $197,511,000 | $242,065,000 | — | — | — | — |
| Med Tech Segment | $149,954,000 | $126,653,000 | $106,403,000 | $96,687,000 | — | — | — | — |
| Access | — | — | — | — | — | — | $94,299,000 | $94,730,000 |
| Endovascular Therapies | — | — | — | — | — | — | $112,706,000 | $119,901,000 |
| Med Device | — | — | — | — | $237,502,000 | $235,279,000 | $223,138,000 | — |
| Med Tech | — | — | — | — | $78,717,000 | $55,731,000 | $41,019,000 | — |
| Oncology | — | — | — | — | — | — | $57,152,000 | $56,003,000 |
| Oncology Surgery | — | — | — | — | — | — | $57,152,000 | $56,003,000 |
| Peripheral Vascular | — | — | — | — | — | — | $112,706,000 | $119,901,000 |
| Vascular Access | — | — | — | — | — | — | $94,299,000 | $94,730,000 |
| Vascular Interventions and Therapies | — | — | — | — | — | — | $112,706,000 | $119,901,000 |
Key facts
CIK
1275187
CUSIP
03475V101
13F (30d)
128 filings
128 filers
Visit website
Investor relations